Table 4 Efficacy Measures Stratified by Line of Therapy

From: Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation

Outcome

Controls (N = 52)

Mut-positive (N = 26)

P-value

Real-world progression free survival by line of therapy (mo)

 First

7.9

21.1

0.0046

 Second or later

3.4

2.5

0.43

Overall response rate by line of therapy—no. with response/no. evaluable (%)

 First

8/28 (29)

13/19 (68)

0.007

 Second or later

0/11 (0)

1/5 (20)

0.12

  1. A subset analysis to compare ORR and rwPFS by line of therapy in which platinum-based treatment was initiated was performed
Back to article page